Your browser doesn't support javascript.
loading
Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy.
Schroeder, Cornelia; Navid-Hill, Elham; Meiners, Jan; Hube-Magg, Claudia; Kluth, Martina; Makrypidi-Fraune, Georgia; Simon, Ronald; Büscheck, Franziska; Luebke, Andreas M; Goebel, Cosima; Lang, Dagmar S; Weidemann, Sören; Neubauer, Emily; Hinsch, Andrea; Jacobsen, Frank; Lebok, Patrick; Michl, Uwe; Pehrke, Dirk; Huland, Hartwig; Graefen, Markus; Schlomm, Thorsten; Sauter, Guido; Höflmayer, Doris.
Afiliação
  • Schroeder C; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Navid-Hill E; General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Meiners J; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hube-Magg C; General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Kluth M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Makrypidi-Fraune G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Büscheck F; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Luebke AM; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Goebel C; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lang DS; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Weidemann S; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Neubauer E; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hinsch A; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Jacobsen F; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lebok P; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Michl U; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Pehrke D; Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Huland H; Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Graefen M; Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schlomm T; Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Sauter G; Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Höflmayer D; Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Oncotarget ; 10(48): 4973-4986, 2019 Aug 13.
Article em En | MEDLINE | ID: mdl-31452838
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha